Evidence map›Paper›PMID 31497252›Full record

ArticleOncotarget2019

Repurposed quinacrine synergizes with cisplatin, reducing the effective dose required for treatment of head and neck squamous cell carcinoma.

Jennifer Bryant, Nikolaos Batis, Anna Clara Franke, Gabriella Clancey, Margaret Hartley, Gordon Ryan, Jill Brooks, Andrew D Southam, Nicholas Barnes, Joanna Parish and 4 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Drug repurposing-an emerging strategy in cancer therapeutics.Naunyn-Schmiedeberg's archives of pharmacology · 2022
    Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Jennifer BryantInstitute of Head and Neck Studies and Education (InHANSE), University of Birmingham, Birmingham, UK.
Nikolaos BatisInstitute of Head and Neck Studies and Education (InHANSE), University of Birmingham, Birmingham, UK.
Anna Clara FrankeInstitute of Head and Neck Studies and Education (InHANSE), University of Birmingham, Birmingham, UK.
Gabriella ClanceyInstitute of Head and Neck Studies and Education (InHANSE), University of Birmingham, Birmingham, UK.
Margaret HartleyInstitute of Head and Neck Studies and Education (InHANSE), University of Birmingham, Birmingham, UK.
Gordon RyanInstitute of Head and Neck Studies and Education (InHANSE), University of Birmingham, Birmingham, UK.
Jill BrooksInstitute of Head and Neck Studies and Education (InHANSE), University of Birmingham, Birmingham, UK.
Andrew D SouthamSchool of Biosciences, University of Birmingham, Birmingham, UK.
Nicholas BarnesInstitute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Joanna ParishInstitute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Sally RobertsInstitute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Farhat KhanimSchool of Biomedical Sciences, Institute of Clinical Sciences, University of Birmingham, Birmingham, UK.
Rachel SpruceInstitute of Head and Neck Studies and Education (InHANSE), University of Birmingham, Birmingham, UK.
Hisham MehannaInstitute of Head and Neck Studies and Education (InHANSE), University of Birmingham, Birmingham, UK.
University of Birmingham · GBUniversity Hospitals Birmingham NHS Foundation Trust · GB

Funding

Medical Research Council MR/M009157/1Medical Research Council MR/N023498/1
6 · The paper itself

Abstract

Despite highly toxic treatments, head and neck squamous cell carcinoma (HNSCC) have poor outcomes. There is an unmet need for more effective, less toxic therapies. Repurposing of clinically-approved drugs, with known safety profiles, may provide a time- and cost-effective approach to address this need. We have developed the AcceleraTED platform to repurpose drugs for HNSCC treatment; using

Indexed as

drug repositioningdrug repurposinghead and neck cancermepacrinequinacrine

Identifiers

PMID31497252
PMCPMC6718257
OpenAlexW2973602879

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.